ImmuPharma (LON:IMM) Stock Price Down 6.3% – Here’s Why

Shares of ImmuPharma plc (LON:IMM) traded down 6.3% during mid-day trading on Friday . The company traded as low as GBX 10.70 ($0.14) and last traded at GBX 11.60 ($0.15). 3,961,091 shares changed hands during trading, a decline of 53% from the average session volume of 8,360,403 shares. The stock had previously closed at GBX 12.38 ($0.16).

ImmuPharma Trading Down 6.3%

The stock has a 50-day simple moving average of GBX 8.95 and a 200-day simple moving average of GBX 4.69. The company has a market cap of £58.32 million, a price-to-earnings ratio of -13.03 and a beta of 1.53.

ImmuPharma (LON:IMM) last announced its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. As a group, research analysts expect that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.